Participant ID						

Eligibility form

Visit 1 Screening- Inclusion Criteria Date: ___/___/____

Question	Answer
Age 18 or over	○ Yes ○ No
Able to provide informed consent	○ Yes ○ No
Capable of complying with all trial procedures and of completing the trial, in the opinion of the investigator	○ Yes ○ No
Bronchiectasis, confirmed by computed tomography (CT), showing bronchiectasis in 1 or more lobes	○ Yes ○ No
Normally produces sputum on a daily basis	○ Yes ○ No
Able to provide a sputum sample at the screening visit	○ Yes ○ No
Active neutrophilic inflammation at screening indicated by a positive NEATstik (Neutrophil Elastase Airways Test) result (b)	○ Yes ○ No

(b) *A positive NEATstik test is equivalent to a NE concentration of 8µg/ml in sputum using the Proaxsis active NE immunoassay. If NEATstik is not available for screening, a frozen sputum sample will be shipped to the central laboratory in Dundee where the immunoassay will be performed and used to confirm eligibility.*

Participant ID						

Visit 1 Screening- Exclusion Criteria

Date: ___/___/____

Question	Answer
Enrolled previously in the trial 3 times	○ Yes ○ No
Respiratory infection or bronchiectasis exacerbation 4 weeks prior to screening	○ Yes ○ No
Antibiotic or corticosteroid 4 weeks prior to screening	○ Yes ○ No
Active allergic bronchopulmonary aspergillosis (defined by International Society for Human and Animal Mycology criteria) on steroids and/or anti-fungals	○ Yes ○ No
Nontuberculous mycobacterial infection on antibiotic therapy	○ Yes ○ No
Immunodeficiency on immunoglobulin replacement	○ Yes ○ No
A primary diagnosis of COPD or asthma (a secondary diagnosis of COPD or asthma is permitted)	○ Yes ○ No
Cystic fibrosis	○ Yes ○ No
Active malignancy except non-melanoma skin cancer	○ Yes ○ No
Currently taking Brensocatib	○ Yes ○ No
Use of any investigational drugs within five times of the elimination half-life after the last dose or within 30 days, whichever is longer. Current enrolment in non-interventional, observational studies will be allowed	○ Yes ○ No
Currently pregnant or breast-feeding	○ Yes ○ No
Women of childbearing age and not practicing an acceptable method of birth control	○ Yes ○ No

Participant ID						

Visit 2 Baseline & randomisation -Inclusion Criteria Date: ___/___/____

Question	Answer
Age 18 or over	○ Yes ○ No
Able to provide informed consent	○ Yes ○ No
Capable of complying with all trial procedures and of completing the trial, in the opinion of the investigator	○ Yes ○ No
Bronchiectasis, confirmed by computed tomography (CT), showing bronchiectasis in 1 or more lobes	○ Yes ○ No
Normally produces sputum on a daily basis	○ Yes ○ No
Able to provide a sputum sample at the screening visit	○ Yes ○ No
Has provided a sputum sample BETWEEN screening and baseline visit	○ Yes ○ No
Active neutrophilic inflammation at screening indicated by a positive NEATstik (Neutrophil Elastase Airways Test) result (b)	○ Yes ○ No

b) A positive NEATstik test is equivalent to a NE concentration of 8µg/ml in sputum using the Proaxsis active NE immunoassay. If NEATstik is not available for screening, a frozen sputum sample will be shipped to the central laboratory in Dundee where the immunoassay will be performed and used to confirm eligibility.

If 'Active neutrophilic inflammation at screening indicated by a positive NEATstik (Neutrophil Elastase Airways Test) result (b)' is equal to 'NO' answer this question:	
Active neutrophilic inflammation at BASELINE indicated by a positive NEATstik (Neutrophil Elastase Airways Test) result (b) (b) A positive NEATstik test is equivalent to a NE concentration of 8µg/ml in sputum using the Proaxsis active NE immunoassay.	○ Yes ○ No

Participant ID						

Visit 2 Baseline & randomisation -Exclusion Criteria Date: ___/___/____

Question	Answer
Enrolled previously in the trial 3 times	○ Yes ○ No
Respiratory infection or bronchiectasis exacerbation 4 weeks prior to screening	○ Yes ○ No
If 24.2 is Yes, answer the following Respiratory infection or bronchiectasis exacerbation BETWEEN screening and randomisation	○ Yes ○ No
Antibiotic or corticosteroid 4 weeks prior to screening	○ Yes ○ No
If 'Antibiotic or corticosteroid 4 weeks prior to screening' is equal to 'YES' answer this question: Antibiotic or corticosteroid BETWEEN screening and randomisation	○ Yes ○ No
Active allergic bronchopulmonary aspergillosis (defined by International Society for Human and Animal Mycology criteria) on steroids and/or anti-fungals	○ Yes ○ No
Nontuberculous mycobacterial infection on antibiotic therapy	○ Yes ○ No
Immunodeficiency on immunoglobulin replacement	○ Yes ○ No
A primary diagnosis of COPD or asthma (a secondary diagnosis of COPD or asthma is permitted)	○ Yes ○ No
Cystic fibrosis	○ Yes ○ No
Active malignancy except non-melanoma skin cancer	○ Yes ○ No
Currently taking Brensocatib	○ Yes ○ No
Use of any investigational drugs within five times of the elimination half-life after the last dose or within 30 days, whichever is longer. Current enrolment in non-interventional, observational studies will be allowed	○ Yes ○ No
Currently pregnant or breast-feeding	○ Yes ○ No
Women of childbearing age and not practicing an acceptable method of birth control	○ Yes ○ No

Participant ID						

Visit 2 Baseline & randomisation -Intervention Specific Exclusion Criteria

Date: ___/___/____

ARM 2- DISULFIRAM (Closed to recruitment)

ARM 3 - DIPYRIDAMOLE

Question	Answer
Currently on Dipyridamole (patients should have a washout period of at least 30 days from last dose if they have previously received this medication)	○ Yes ○ No
Hypersensitivity to Dipyridamole	○ Yes ○ No
Participant, or investigator objects to randomisation to Dipyridamole	○ Yes ○ No
Currently on dual antithrombotic therapy (aspirin or P2Y12 inhibitor plus anticoagulation)	○ Yes ○ No
Current on direct oral anticoagulants (Dabigatran, Rivaroxaban, Edoxaban, Apixaban, Betrixaban or drugs in the same class) or long-term warfarin	○ Yes ○ No
Any major trauma or haemorrhage including gastrointestinal bleeding, operation within the past 30 days	○ Yes ○ No
Coagulation disorder	○ Yes ○ No
Severe coronary artery disease (unstable angina, recent myocardial infarct in 30 days, decompensated/unstable severe left systolic dysfunction, uncontrolled heart failure)	○ Yes ○ No
Myasthenia gravis	○ Yes ○ No

Participant ID						

ARM 4 – DOXYCYCLINE

Question	Answer
Currently on Doxycycline (patients should have a washout period of at least 30 days from last dose if they have previously received this medication)	○ Yes ○ No
Hypersensitivity to Doxycycline	○ Yes ○ No
Participant, or investigator objects to randomisation to Doxycycline	○ Yes ○ No
Myasthenia gravis	○ Yes ○ No
Systemic Lupus Erythematosus	○ Yes ○ No
Chronic Liver Disease	○ Yes ○ No
Porphyria	○ Yes ○ No
Alcohol dependence	○ Yes ○ No
Suspected Syphilis	○ Yes ○ No

Participant ID						

Visit 2 - Baseline and randomisation – Confirmation of eligibility

Number	Question	Answers
	Eligible for **Arm 1: Standard care**?	○ Yes ○ No
	Eligible for **Arm 3: Dipyridamole**?	○ Yes ○ No
	Eligible for **Arm 4: Doxycycline**?	○ Yes ○ No

Eligibility review completed by *(must be a Dr on delegation log):*

Signature:

Name:

Date: